Chitosan-coated boron nitride nanospheres enhance delivery of CpG oligodeoxynucleotides and induction of cytokines

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1783-1793

  Zhang, Huijie ^a,b   Chen, Song ^c   Zhi, Chunyi ^d   Yamazaki, Tomohiko ^a,b   Hanagata, Nobutaka ^a,b,e  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^d CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^e Nanotechnology Innovation Station   (Japan)

Author keywords

Boron nitride nanospheres; Chitosan; Cpg oligodeoxynucleotides; Cytokines; Drug delivery

Indexed keywords

BORON NITRIDE NANOTUBE; CHITOSAN; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DRUG CARRIER; INTERLEUKIN 6; LIPOFECTAMINE; TUMOR NECROSIS FACTOR ALPHA;

ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; ZETA POTENTIAL;

BORON NITRIDE NANOSPHERES; CHITOSAN; CPG OLIGODEOXYNUCLEOTIDES; CYTOKINES; DRUG DELIVERY;

BORON COMPOUNDS; CELL LINE; CELL SURVIVAL; CHITOSAN; CYTOKINES; DRUG CARRIERS; HUMANS; NANOSPHERES; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84877298118     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S43251     Document Type: Article

References (49)

1. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4(4):248-257.
2. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546-549.
3. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009;61(3): 195-204.
4. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740-745.
5. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329-368.
6. Bauer S, Kirschning CJ, Häcker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98(16):9237-9242.
7. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996;93(7):2879-2883.
8. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801.
9. Chen HC, Sun B, Tran KK, Shen H. Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials. 2011;32(6): 1731-1737.
10. Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Delivery Rev. 2009;61(3):248-255.
11. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009;61(3):256-262.
12. Murad YM, Clay TM. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs. 2009;23(6):361-375.
13. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5(6):471-484.
14. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 2004;97(1):1-17.
15. Kurreck J. Antisense technologies - improvement through novel chemical modifications. Eur J Biochem. 2003;270(8):1628-1644.
16. Agrawal S, Zhao QY. Antisense therapeutics. Curr Opin Chem Biol. 1998;2(4):519-528.
17. Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood. 1998;92(5):1617-1625.
18. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004;10(2):187-192.
19. Zhu Y, Meng W, Li X, Gao H, Hanagata N. Design of mesoporous silica/cytosine-phosphodiester-guanine oligodeoxynucleotide complexes to enhance delivery efficiency. J Phys Chem C. 2010;115(2):447-452.
20. Wilson KD, de Jong SD, Tam YK. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Deliv Rev. 2009;61(3):233-242.
21. Bianco A, Hoebeke J, Godefroy S, et al. Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. J Am Chem Soc. 2004;127(1):58-59.
22. Rattanakiat S, Nishikawa M, Funabashi H, Luo D, Takakura Y. The assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic structures and its effect on immunostimulatory activity. Biomaterials. 2009;30(29):5701-5706.
23. Standley SM, Mende I, Goh SL, et al. Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Bioconjug Chem. 2006;18(1):77-83.
24. Chopra NG, Luyken RJ, Cherrey K, et al. Boron-nitride nanotubes. Science. 1995;269(5226):966-967.
25. Zhi CY, Bando Y, Tang CC, Xie RG, Sekiguchi T, Golberg D. Perfectly dissolved boron nitride nanotubes due to polymer wrapping. J Am Chem Soc. 2005;127(46):15996-15997.
26. Gao ZH, Zhi CY, Bando Y, Golberg D, Serizawa T. Isolation of individual boron nitride nanotubes via peptide wrapping. J Am Chem Soc. 2010;132(14):4976-4977.
27. Golberg D, Bando Y, Tang CC, Zhi CY. Boron nitride nanotubes. Adv Mater. 2007;19(18):2413-2432.
28. Chen X, Wu P, Rousseas M, et al. Boron nitride nanotubes are noncytotoxic and can be functionalized for interaction with proteins and cells. J Am Chem Soc. 2009;131(3):890-891.
29. Jonsson E, Simonsen L, Karlsson M, Larsson R. The hollow fiber model: a new method for in vivo-evaluation of antitumor effect, toxicity and pharmacokinetics of new anticancer drugs. Ann Oncol. 1998;9:44.
30. Ciofani G, Raffa V, Menciassi A, Cuschieri A. Boron nitride nanotubes: an innovative tool for nanomedicine. Nano Today. 2009;4(1):8-10.
31. Zhi CY, Meng WJ, Yamazaki T, et al. BN nanospheres as CpG ODN carriers for activation of Toll-like receptor 9. J Mater Chem. 2011; 21(14):5219-5222.
32. Agrawal P, Strijkers GJ, Nicolay K. Chitosan-based systems for molecular imaging. Adv Drug Deliv Rev. 2010;62(1):42-58.
33. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 2010;62(1):59-82.
34. Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81(3):463-469.
35. Wu KY, Wu M, Fu ML, et al. A novel chitosan CpG nanoparticle regulates cellular and humoral immunity of mice. Biomed Environ Sci. 2006;19(2):87-95.
36. Ravi Kumar MNV, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25(10):1771-1777.
37. Tang CC, Bando Y, Huang Y, Zhi CY, Golberg D. Synthetic routes and formation mechanisms of spherical boron nitride nanoparticles. Adv Funct Mater. 2008;18(22):3653-3661.
38. Meng WJ, Yamazaki T, Nishida Y, Hanagata N. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. BMC Biotechnol. 2011;11:88.
39. Soares DCF, Ferreira TH, Ferreira CA, Cardoso VN, de Sousa EMB. Boron nitride nanotubes radiolabeled with 99 mTc: preparation, physicochemical characterization, biodistribution study, and scintigraphic imaging in Swiss mice. Int J Pharm. 2012;423(2):489-495.
40. Yan LY, Poon YF, Chan-Park MB, Chen Y, Zhang Q. Individually dispersing single-walled carbon nanotubes with novel neutral pH water-soluble chitosan derivatives. J Phys Chem C. 2008;112(20):7579-7587.
41. Ozarkar S, Jassal M, Agrawal AK. Improved dispersion of carbon nanotubes in chitosan. Fibers Polym. 2008;9(4):410-415.
42. Shvartzman-Cohen R, Levi-Kalisman Y, Nativ-Roth E, Yerushalmi-Rozen R. Generic approach for dispersing single-walled carbon nanotubes: the strength of a weak interaction. Langmuir. 2004;20(15): 6085-6088.
43. Zhu YF, Ikoma T, Hanagata N, Kaskel S. Rattle-type Fe(3)O(4)@SiO(2) hollow mesoporous spheres as carriers for drug delivery. Small. 2010;6(3):471-478.
44. Zhang H, Yamazaki T, Zhi C, Hanagata N. Identification of a boron nitride nanosphere-binding peptide for the intracellular delivery of CpG oligodeoxynucleotides. Nanoscale. 2012;4(20):6343-6350.
45. Strand SP, Lelu S, Reitan NK, Davies CD, Artursson P, Varum KM. Molecular design of chitosan gene delivery systems with an optimized balance between polyplex stability and polyplex unpacking. Biomaterials. 2010;31(5):975-987.
46. Ma PL, Lavertu M, Winnik FM, Buschmann MD. New insights into chitosan-DNA interactions using isothermal titration microcalorimetry. Biomacromolecules. 2009;10(6):1490-1499.
47. Danielsen S, Vårum KM, Stokke BT. Structural analysis of chitosan mediated DNA condensation by AFM: influence of chitosan molecular parameters. Biomacromolecules. 2004;5(3):928-936.
48. Karidi K, Garoufis A, Tsipis A, Hadjiliadis N, den Dulk H, Reedijk J. Synthesis, characterization, in vitro antitumor activity, DNA-binding properties and electronic structure (DFT) of the new complex cis-(Cl,Cl) Ru(II)Cl2(NO+)(terpy) Cl. Dalton Trans. 2005;7:1176-1187.
49. Dhar S, Nethaji M, Chakravarty AR. Steric protection of a photosensitizer in a N,N-bis 2-(2-pyridyl)ethyl -2-phenylethylamine-copper(II) bowl that enhances red light-induced DNA cleavage activity. Inorg Chem. 2005;44(24):8876-8883.